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The Cardiac L-Type Ca2D Channel is Downregulated by Ischemic and
Pharmacological Preconditioning
Jorge A. Sanchez, German Gonza´lez, Daniel Zaldı´var, Elba D. Carrillo,
Maria C. Garcı´a.
Ischemic preconditioning (IP) is a phenomenon in which briefs periods of is-
chemia activate endogenous mechanisms that protect cardiomyocytes from
subsequent ischemia. Pharmacological Preconditioning (PPC) with mitochon-
drial ATP-sensitive Kþ channel (mitoKATP) openers such as diazoxide mimics
IP. However, changes in Ca2þ homeostasis during IP and PPC, particularly in
Ca2þ channel activity, are poorly understood. We investigated the effects of IP
and PPC on cardiac L-type Ca2þ channels.
IP was achieved by four cycles of ischemia-reperfusion in isolated hearts. PPC
was induced in isolated hearts and in dissociated cardiomyocytes from adult
rats by preincubation withdiazoxide. We measured reactive oxygen species
(ROS) production and Ca2þ signals associated with action potentials using-
fluorescent probes. L-type currents were measured with the whole-cell patch-
clamp technique. Levels of the alpha1c subunit of L-type channelsin the cellular
membrane were measured by Western blot.
IP produced a 20% reduction in alpha1c subunit levels. PPC was accompanied
by a 50% reduction in alpha1c subunit levels, and by a reversible fall in L-type
current amplitude and Ca2þtransients. These effects were prevented by the
ROS scavenger N-acetyl-L-cysteine (NAC) or by the mitoKATP channel
blocker5-hydroxydecanoate (5-HD). PPC significantly reduced infarct size,
an effect blocked by NAC and 5-HD. Nifedipine alsoconferred protection
against infarction when applied during the reperfusion period. Downregulation
of the alpha1c subunit andCa
2þ channel function were prevented in part by the
protease inhibitor leupeptin.
We conclude that IP andPPC downregulate the alpha1c subunit by a proteolytic
process in which ROS are involved. This in turn leads to a reduced Ca2þ influx
and attenuates Ca2þ overload during reperfusion.
Grants: CONACYT: 60880 (J.S) and 102100 (M.C.G).
3080-Pos Board B185
Expression Pattern of L-Type Calcium Channel Subunits in Human and
Murine Atherosclerosis
Ann Kristin Boehnke, Margarete Odenthal, Michael Gawenda, Jan Matthes,
Peter Hein, Stefan Herzig.
Cardiovascular L-type Ca2þ-channels (LTCC) are heteromeric protein com-
plexes consisting of a pore-forming Cav1.2 (a1C) and several auxiliary subunits.
Major determinants of channel function include the composition of the hetero-
meric complex, but also subunit transcript regulation by splicing. This is of
particular importance since splicing patterns may change under pathophysio-
logical conditions, such as atherosclerosis. In human atherosclerosis, arterial
smooth muscle Cav1.2 isoforms containing exon 21 were reported to be re-
placed by a single isoform containing the alternative exon 22. We have recently
shown that this splice shift has major effects on LTCC: co-expressing a
b3-subunit together with a1C70 (containing exon 21) led to markedly reduced
current density compared to a1C77 (containing exon 22). Co-expression of
a b2-subunit with either a1C70 or a1C77 had the opposite effect.
In the present work we sought to determine the expression pattern of LTCC
subunits in both murine and human atherosclerotic arterial tissue. Murine aorta
was isolated from wild-type and atherosclerotic apoE-knockout mice. Samples
of human atherosclerotic arteries were obtained from patients undergoing arte-
rial bypass surgery, and vascular smooth muscle cells were isolated by laser
microdissection. qRT-PCR was used to determine LTCC subunit expression.
In murine aortic tissue we were able to detect exon 21- as well as exon
22-containing Cav1.2 subunit mRNA. Furthermore, we detected b1-, b2- and
b3-subunit mRNA with expression of b1-subunits being significantly reduced
in atherosclerotic aortic tissue compared to non-atherosclerotic tissue. In hu-
man atherosclerotic tissue samples, we found mRNA expression of all four
b-subunits, b1-4, with a trend towards b2-subunit mRNA being more abundant
than that of other b-subunit isoforms.
Given the functional impact of LTCC composition, our data support the idea
that altered expression profiles of b-subunits might affect channel function in
atherosclerosis.
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Novel Blockers of T-Type Calcium Channels Modify Gating
Pamela Bergson, Victor N. Uebele, John J. Renger, Dorothy A. Hanck.
Physiological and biophysical studies of T-type calcium channels, a subclass
of voltage gated ion channels with a characteristically low voltage threshold
for activation, have been hampered by a lack of selective antagonists, andno specific blockers of T-type calcium channels are currently clinically avail-
able. Several compounds have recently been identified that block calcium en-
try into cells expressing T-type calcium channels (Uebele et al, Cell Biochem
Biophys 55:81). These compounds include an amide (TTA-A2) and a quinazo-
linone (TTA-Q4). We used whole cell patch clamp to examine block by these
two experimental drugs in HEK 293 cells heterogeneously expressing CaV3.1.
When holding potential was 110 mV, the TTAs blocked resting T-type chan-
nels with sub-micromolar affinity (ED50=890nM for TTA-A2 and 560nM for
TTA-Q4). Block was voltage dependent, and the affinity rose by approxi-
mately 5-fold when tested at 20 mV (ED50=200nM for TTA-A2 and
130nM for TTA-Q4). Although the extent of block was voltage dependent,
the kinetics were not. Neither the rate of development of block (t=100ms
for TTA-A2 and 178ms for TTA-Q4) nor the recovery from block (t=1.2
sec for TTA-A2 and 4 sec for TTA-Q4) changed with voltage, consistent
with a guarded receptor model. An examination of gating current revealed
that both TTA-A2 and TTA-Q4 inhibited the movement of gating charge at
depolarized potentials, without shifting the half-point of activation. These
findings suggest that TTA-A2 and TTA-Q4 inhibit T-type current by restrict-
ing the movement of one or more voltage sensors, which may prevent the
opening of the channel.
Support: T32HL007381 (PB), RO1HL065680.3082-Pos Board B187
Amiloride Docking to T-Type Calcium Channels
Manuel Rivera, Osbaldo Lo´pez-Charcas, Juan C. Gomora.
Amiloride and its analogues are small molecules frequently used as
potassium-sparing diuretics. These drugs have been utilized for decades in
the treatment of diseases like hypertension. They are known for interacting
with the sodium/hydrogen antiporter, sodium/calcium exchanger, and mainly
with the epithelial sodium channel (ENaC). However, amiloride has also
served as a pharmacological tool for the study of T-type calcium channels.
The structural basis for these interactions has not been elucidated as crystal
structures of these proteins are not known yet. Nevertheless, a possible inter-
pretation of the amiloride blocking effects is that these proteins share com-
mon structural homologies. In this work we examined the interaction of
amiloride with T-type voltage-gated calcium channels (CaV3), whose protein
structure was available by computational modeling approach. Using molec-
ular docking software, amiloride and related molecules were docked to
CaV3 channels model structures in order to unveil potential interaction
sites. The resulting predictions were experimentally validated by assessing
the effect of amiloride on CaV3 channels expressed in HEK-293 cells,
with the use of the whole-cell patch-clamp technique. The results showed
differential sensitivity of CaV3 family members to amiloride, being CaV3.2
the most sensitive to the diuretic. The difference with CaV3.1 and CaV3.3
was more than an order of magnitude. These results offer the possibility
to propose a model of electrostatic interactions of the putative sites with
members of CaV3 family, which interact with drugs that share a similar
structure with amiloride.
Supported by CONACYT J50250Q and ICYTDF PICDS08-28.3083-Pos Board B188
Interaction of Diltiazem with an Intracellularly Accessible Binding Site
on CaV1.2
Stanislav Beyl, Waheed Shabbir, Eugen Timin, Denise Schellmann,
Thomas Erker, Annette Hohaus, Gregory H. Hockerman, Steffen Hering.
Diltiazem inhibits CaV1.2 channels and is widely used in clinical practiceto
treat cardiovascular diseases. Binding determinants for diltiazem are located
on segments IIIS6, IVS6 and the selectivity filter of the pore forming a1 sub-
unit of CaV1.2. Here we elucidate the access path of Diltiazem to its binding
site making use of membrane impermeable quaternary derivative qDil and
mutant a1 subunits. qDil was synthesized and applied to the intracellular
side (via the patch pipette) or to the extracellular side of the membrane (by
bath perfusion). qDil inhibits CaV1.2 when applied to the intracellular side
of the membrane in a use-dependent manner (5954% at 300 mM) and induced
only a low level of tonic (non use-dependent) block (1652% at 300 mM)
when applied to the extracellular side of the membrane. Mutations in IIIS6
and IVS6 reduced sensitivity to intracellularly applied qDil.Our study
demonstrates intracellular access of quaternary diltiazem and its interaction
with previously identified determinants of BTZ binding pocket. Recovery
from block by diltiazem was found to be voltage independent, which is in
contrast with the pronounced voltage dependent recovery from block by
phenylalkylamines.
